Juvenile Diabetes Research Foundation Canada

2550 Victoria Park Avenue, Suite 800
Toronto, ON M2J 5A9
President & CEO: Dave Prowten
Board Chair: Matt Varey

Website: www.jdrf.ca
Charitable Reg. #: 11897 6604 RR0001
Sector: Health
Operating Charity

Donor Accountability

Grade: B

The grade is based on the charity's public reporting of the work it does and the results it achieves.

Financial Transparency

Audited financial statements for current and previous years available on the charity's website [ Audited financial statement for most recent year ]

Need for Funding

Funding Reserves Program Costs

Spending Breakdown

Full-time staff #105

Avg. Compensation $69,865

Top 10 Staff Salary Range

$350k + 0
$300k - $350k 0
$250k - $300k 0
$200k - $250k 1
$160k - $200k 0
$120k - $160k 3
$80k - $120k 6
$40k - $80k 0
< $40k 0
Information from most recent CRA Charities Directorate filings for F2014

About Juvenile Diabetes Research Foundation Canada:

Founded in 1974 by parents of children with diabetes, Juvenile Diabetes Research Foundation Canada (JDRF) is the largest funder and advocate for Type 1 diabetes (T1D) research. Its focus is to find a cure for T1D and its complications. JDRF reports that 300,000 Canadians live with T1D. On average, T1D management requires 1,460 insulin shots a year. T1D often leads to life-threatening and debilitating complications which may include kidney failure, blindness, heart disease, stroke, nerve damage and amputation. The frequency of T1D among children under the age of 14 is rising, with rates doubling over the last 20 years in children under 5 years old. JDRF funds research focused on three main ideas: cure, prevention and treatment. Its main research focus includes immune therapies, regeneration, replacement, prevention, artificial pancreas, glucose control therapy and complications prevention.

In F2015, Juvenile Diabetes Research Foundation Canada awarded 121 new research grants, funding 200 global institutions and 39 research projects in Canada. The grants also funded 50 active clinical trials globally. In F2015, 350 principal investigators received funding from JDRF.

JDRF’s research surrounding an artificial pancreas is a revolutionary advance in diabetes care. In F2014, the artificial pancreas received USFDA approval. JDRF's research milestones also include beta cell encapsulation (implanting stem cells to "heal" T1D). In F2015, the first cohort of Canadian participants began testing the safety of the encapsulation product. In F2016, JDRF plans to test the tolerability and efficacy of the product, which could allow those with T1D to live free of insulin injections. Finally, JDRF’s stem cell research focuses on converting stem cells into insulin-producing pancreatic cells. This can rapidly reverse diabetes following a transplant.  

Financial Review:

Juvenile Diabetes Research Foundation Canada is a Major 100 charity, with donations of $20m in F2015. Its fundraising costs are 49% of donations and its administrative costs are 21% of revenues. JDRF spends more on fundraising than it does on T1D programs and research due to high-cost fundraising events. For every $1 donated to the charity, 30 cents is put towards its programs, falling well below Ci’s reasonable range. The charity’s funding reserves of $8.5m include $86k in donor-endowed funds. This results in a program cost coverage ratio, excluding donor-endowed funds, of 94%. This means that the charity can cover 11 months of its annual programs using its existing reserves.

This charity report is an update that is being reviewed by Juvenile Diabetes Research Foundation Canada. Changes and edits may be forthcoming.

Updated on August 2, 2016 by Lynn Tay.

Financial Ratios

Fiscal year ending December
Administrative costs as % of revenues 20.9%18.7%14.4%
Fundraising costs as % of donations 48.8%47.1%52.4%
Program cost coverage (%) 94.7%105.7%184.1%

Summary Financial Statements

All figures in $000s
Donations 20,00520,90823,064
Lotteries (net) 272427428
Investment income 12823530
Total revenues 20,40521,57023,522
Program costs 1,1181,1841,128
Grants 7,8628,7105,780
Administrative costs 4,2333,9973,371
Fundraising costs 9,7579,83912,096
Cash flow from operations (2,565)(2,160)1,147
Funding reserves 8,50110,45512,719
Note: Ci has used the F2014 financial statements reported in the charity’s 2015 audited financial statements, and the F2013 financial statements reported in the charity’s 2014 audited financial statements. Ci has adjusted amortization of assets affecting expenses by ($90k) in F2015, by ($90k) in F2014, and by ($67k) in F2013.

Comments added by the Charity:

These comments refer to a previous Charity Intelligence profile:

JDRF directs funds to deliver both near-term benefits for people who live with type 1 diabetes and, ultimately, a cure. Our research focus is on two distinct and related aims of science leading to a cure and science leading to better treatments. JDRF also provides outreach support services, volunteer and advocacy opportunities.

Canada’s excellence in diabetes research and breakthroughs continues in the creation of the JDRF Canadian Clinical Trial Network. Launched in 2010 through a partnership with the Government of Canada, JDRF CCTN began as a $33.9M investment to accelerate the testing of new technologies and treatments for Canadians living with type 1 diabetes and its complications.

JDRF is positively impacting the lives and futures of people living with diabetes. Thanks to the support of our generous donors, JDRF has made significant advancements and progress toward positive health outcomes for people living with type 1 diabetes. For example:

  • JDRF-funded research with industry partners on immune therapies is progressing to the most advanced stages of clinical testing
  • JDRF now funds over 50 human clinical trials, as opposed to five in 2003.
  • JDRF is perfecting insulin treatments, a critical component of JDRF’s Artificial Pancreas Project and impact on the daily lives of those living with type 1 diabetes.
  • Recent advances in diabetic eye disease, funded in part by JDRF, hold the potential to help prevent and reverse eye disease in people with type 1 diabetes.

We remain committed to a cure while investing in better treatments for today.

Go to top